ReCode Therapeutics CEO and leadership

Dr. Lockhart is an accomplished biotech executive with more than 25 years of experience across all phases of drug discovery, drug development and technology development.

Prior to becoming president and CSO of ReCode Therapeutics in January 2022, he served as CEO and president of the company since March 2020. Prior to serving as CEO and President of ReCode, he was CEO and President of its predecessor, TranscripTx from 2014 - 2020. Prior to TranscripTx, he was the Chief Scientific Officer at Amicus Therapeutics from 2006 through 2013. He led a team at Amicus that brought multiple rare disease programs into clinical trials.

Previously, he co-founded Ambit Biosciences, serving as Chief Scientific Officer and President for 5 years, during which the company developed a novel kinase profiling technology and new kinase inhibitors for cancer and other diseases. Prior to Ambit, Dr. Lockhart served as Director of Genomics at the Genomics Institute of the Novartis Research Foundation (GNF). Dr. Lockhart began his biotech career at Affymetrix, where he was the primary inventor and developer of gene expression profiling with DNA microarrays.

Dr. Lockhart received his Ph.D. in Chemistry from Stanford University and was a postdoctoral fellow at the Whitehead Institute in the Biology Department at MIT. He has published more than 80 peer-reviewed scientific articles on pharmacological chaperones, mutation-specific selection of patients for clinical trials, clinical studies with pharmacological chaperones, genomics, kinase technology, kinase inhibitor discovery, and the use of genomic tools to address important biological and biomedical problems. He is also the inventor on more than 40 issued U.S. patents.

Ms. Eastland is a seasoned strategic and financial executive with more than 25 years of experience in corporate finance, corporate development, financial planning and analysis, investor relations and operations.

She previously served as chief financial officer and chief business officer of Rainier Therapeutics, a private biopharmaceutical company focused on developing treatments for bladder cancer. Prior to Rainier, Eastland served as chief financial officer and chief business officer of Cascadian Therapeutics, a publicly traded oncology company that was acquired by Seattle Genetics in 2018. While at Cascadian, Eastland was instrumental in the negotiation and sale of the company, primarily for its product tucatinib, a HER2 targeted breast cancer therapy now marketed as Tukysa:registered:. Before Cascadian, she served as chief financial officer and vice president of operations at VLST Corporation, a private biotechnology company, and also held financial and strategic management positions of increasing responsibility at Dendreon and Amgen.

Eastland received an M.B.A. from Edinburgh University Management School and a B.S. in finance from Colorado State University. Eastland serves on the board of directors for Dynavax Technologies (Nasdaq: DVAX), Graybug Vision (Nasdaq: GRAY) and Harpoon Therapeutics (Nasdaq: HARP).

I am the editor of Recode, where I lead a team of reporters and editors to tell essential stories - in written and audio form - about the tech world and its intersection with everything else.

I joined in 2019 to lead the relaunch of Recode on Vox.com. Since then, I've refocused Recode's work on making an impact, breaking news, and going deep into complex topics so we can reach both Silicon Valley insiders and a much broader audience that's still grasping the importance of tech coverage.

I oversee, conceptualize, and edit work that includes in-depth investigations and features, breaking news scoops, authoritative reported analysis, special projects with a video component, and both narrative and short-form podcasts (Land of the Giants and Recode Daily).

Before this, I was the deputy tech and business editor for BuzzFeed News, where I helped manage our news desk, developed and edited coverage ranging from breaking news to service journalism to enterprise reporting, and worked with my team to develop themed content and story packages. And a few years before that, I was a homepage editor at Wired for three years, where I built and managed the site's daily story budget and homepage and strategized about long-term coverage goals. I also co-edited Wired's Security section.

Dr. Lockhart is an accomplished biotech executive with more than 25 years of experience across all phases of drug discovery, drug development and technology development.

Prior to becoming president and CSO of ReCode Therapeutics in January 2022, he served as CEO and president of the company since March 2020. Prior to serving as CEO and President of ReCode, he was CEO and President of its predecessor, TranscripTx from 2014 - 2020. Prior to TranscripTx, he was the Chief Scientific Officer at Amicus Therapeutics from 2006 through 2013. He led a team at Amicus that brought multiple rare disease programs into clinical trials.

Previously, he co-founded Ambit Biosciences, serving as Chief Scientific Officer and President for 5 years, during which the company developed a novel kinase profiling technology and new kinase inhibitors for cancer and other diseases. Prior to Ambit, Dr. Lockhart served as Director of Genomics at the Genomics Institute of the Novartis Research Foundation (GNF). Dr. Lockhart began his biotech career at Affymetrix, where he was the primary inventor and developer of gene expression profiling with DNA microarrays.

Dr. Lockhart received his Ph.D. in Chemistry from Stanford University and was a postdoctoral fellow at the Whitehead Institute in the Biology Department at MIT. He has published more than 80 peer-reviewed scientific articles on pharmacological chaperones, mutation-specific selection of patients for clinical trials, clinical studies with pharmacological chaperones, genomics, kinase technology, kinase inhibitor discovery, and the use of genomic tools to address important biological and biomedical problems. He is also the inventor on more than 40 issued U.S. patents.